Differential change in fatigue in patients treated with sonidegib in BOLT correlated with geographic region, performance status, metastatic burden, and treatment response. Increase in fatigue was lower in patients responding to treatment. These data support the clinical benefit observed with sonidegib in patients with advanced BCC.
Article